Neuroscience Bulletin

, Volume 29, Issue 5, pp 655–660 | Cite as

Contribution of β-phenethylamine, a component of chocolate and wine, to dopaminergic neurodegeneration: implications for the pathogenesis of Parkinson’s disease

  • Anupom BorahEmail author
  • Rajib Paul
  • Muhammed Khairujjaman Mazumder
  • Nivedita Bhattacharjee


While the cause of dopaminergic neuronal cell death in Parkinson’s disease (PD) is not yet understood, many endogenous molecules have been implicated in its pathogenesis. β-phenethylamine (β-PEA), a component of various food items including chocolate and wine, is an endogenous molecule produced from phenylalanine in the brain. It has been reported recently that long-term administration of β-PEA in rodents causes neurochemical and behavioral alterations similar to that produced by parkinsonian neurotoxins. The toxicity of β-PEA has been linked to the production of hydroxyl radical (.OH) and the generation of oxidative stress in dopaminergic areas of the brain, and this may be mediated by inhibition of mitochondrial complex-I. Another signifi cant observation is that administration of β-PEA to rodents reduces striatal dopamine content and induces movement disorders similar to those of parkinsonian rodents. However, no reports are available on the extent of dopaminergic neuronal cell death after administration of β-PEA. Based on the literature, we set out to establish β-PEA as an endogenous molecule that potentially contributes to the progressive development of PD. The sequence of molecular events that could be responsible for dopaminergic neuronal cell death in PD by consumption of β-PEA-containing foods is proposed here. Thus, long-term over-consumption of food items containing β-PEA could be a neurological risk factor having significant pathological consequences.


oxidative stress hydroxyl radical mitochondrial complex-I α-synuclein Lewy body ubiquitinproteasome system 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    Carlsson A. Treatment of Parkinson’s with L-DOPA. The early discovery phase, and a comment on current problems. J Neural Transm 2002, 109: 777–787.PubMedCrossRefGoogle Scholar
  2. [2]
    Borah A, Mohanakumar KP. Long-term L-DOPA treatment causes indiscriminate increase in dopamine levels at the cost of serotonin synthesis in discrete brain regions of rats. Cell Mol Neurobiol 2007, 27: 985–996.PubMedCrossRefGoogle Scholar
  3. [3]
    Przedborski S, Ischiropoulos H. Reactive oxygen and nitrogen species: weapons of neuronal destruction in models of Parkinson’s disease. Antioxid Redox Signal 2005, 7: 685–693.PubMedCrossRefGoogle Scholar
  4. [4]
    Schapira AH, Gu M, Taanman JW, Tabrizi SJ, Seaton T, Cleeter M, et al. Mitochondria in the etiology and pathogenesis of Parkinson’s disease. Ann Neurol 1998, 44: S89–98.PubMedGoogle Scholar
  5. [5]
    Beal MF. Experimental models of Parkinson’s disease. Nat Rev Neurosci 2001, 2: 325–332.PubMedCrossRefGoogle Scholar
  6. [6]
    Blandini F, Armentero MT. Animal models of Parkinson’s disease. FEBS J 2012, 279: 1156–1166.PubMedCrossRefGoogle Scholar
  7. [7]
    Duan W, Ladenheim B, Cutler RG, Kruman II, Cadet JL, Mattson MP. Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson’s disease. J Neurochem 2002, 80: 101–110.PubMedCrossRefGoogle Scholar
  8. [8]
    Borah A, Mohanakumar KP. L-DOPA induced-endogenous 6-hydroxydopamine is the cause of aggravated dopaminergic neurodegeneration in Parkinson’s disease patients. Med Hypotheses 2012, 79(2): 271–273.PubMedCrossRefGoogle Scholar
  9. [9]
    Borah A, Mohanakumar KP. L-DOPA-induced 6-hydroxydopamine production in the striata of rodents is sensitive to the degree of denervation. Neurochem Int 2010a, 56: 352–362.CrossRefGoogle Scholar
  10. [10]
    Borah A, Mohanakumar KP. Salicylic acid protects against chronic L-DOPA-induced 6-OHDA generation in experimental model of parkinsonism. Brain Res 2010b, 16: 192–199.CrossRefGoogle Scholar
  11. [11]
    Borah A, Mohanakumar KP. Melatonin inhibits 6-hydroxydopamine production in the brain to protect against experimental Parkinsonism in rodents. J Pineal Res 2009a, 47: 293–300.PubMedCrossRefGoogle Scholar
  12. [12]
    Borah A, Mohanakumar KP. Long term L-DOPA treatment causes production of 6 OHDA in the mouse striatum: Involvement of hydroxyl radical. Ann Neurosci 2009b, 16: 160–165.Google Scholar
  13. [13]
    Chen L, Ding Y, Cagniard B, Van Laar AD, Mortimer A, Chi W, et al. Unregulated cytosolic dopamine causes neurodegeneration associated with oxidative stress in mice. J Neurosci 2008, 28: 425–433.PubMedCrossRefGoogle Scholar
  14. [14]
    Dillinger TL, Barriga P, Escarcega S, Jimenez M, Lowe DS, Grivetti LE. Food of the Gods: Cure for humanity? A cultural history of the medicinal and ritual use of chocolate. J Nutr 2000, 130: 2057S–2072S.PubMedGoogle Scholar
  15. [15]
    Ziegleder G, Stojacic E, Stumpf B. Occurrence of betaphenylethylamine and its derivatives in cocoa and cocoa products. Z Lebensm Unters Forsch 1992, 195: 235–238. [Article in German]PubMedCrossRefGoogle Scholar
  16. [16]
    Philips SR. Amphetamine, p-hydroxyamphetamine and b-phenylethylamine in mouse brain and urine after (−)- and (+)-deprenyl administration. J Pharm Pharmacol 1981, 33: 739–741.PubMedCrossRefGoogle Scholar
  17. [17]
    Durden DA, Philips SR, Boulton AA. Identification and distribution of beta-phenylethylamine in the rat. Can J Biochem 1973, 51: 995–1002.PubMedCrossRefGoogle Scholar
  18. [18]
    Pastore P, Favaro G, Badocco D, Tapparo A, Cavalli S, Saccani G. Determination of biogenic amines in chocolate by ion chromatographic separation and pulsed integrated amperometric detection with implemented wave-form at Au disposable electrode. J Chromatogr 2005, 1098: 111–115.CrossRefGoogle Scholar
  19. [19]
    Hurst WJ, Toomey PB. High-performance liquid chromatographic determination of four biogenic amines in chocolate. Analyst 1981, 106: 394–402.PubMedCrossRefGoogle Scholar
  20. [20]
    Bonetta S, Bonetta S, Carraro E, Coïsson JD, Travaglia F, Arlorio M. Detection of biogenic amine producer bacteria in a typical Italian goat cheese. J Food Prot 2008, 71: 205–209.PubMedGoogle Scholar
  21. [21]
    Landete JM, Ferrer S, Polo L, Pardo I. Biogenic amines in wines from three Spanish regions. J Agric Food Chem 2005, 53: 1119–1124.PubMedCrossRefGoogle Scholar
  22. [22]
    Garcia VN, Saurina J, Hernández-Cassou S. Highperformance liquid chromatographic determination of biogenic amines in wines with an experimental design optimization procedure. Anal Chim Acta 2006, 575: 97–105.CrossRefGoogle Scholar
  23. [23]
    Berry MD. Mammalian central nervous system trace amines. Pharmacologic amphetamines, physiologic neuromodulators. J Neurochem 2004, 90: 257–271.PubMedCrossRefGoogle Scholar
  24. [24]
    Paterson IA, Juorio AV, Boulton AA. Phenylethylamine: a modulator of catecholamine transmission in the mammalian central nervous system? J Neurochem 1990, 55: 1827–1837.PubMedCrossRefGoogle Scholar
  25. [25]
    Saravanan KS, Sindhu KM, Senthilkumar KS, Mohanakumar KP. L-deprenyl protects against rotenone-induced, oxidative stress-mediated dopaminergic neurodegeneration in rats. Neurochem Int 2006, 49: 28–40.PubMedCrossRefGoogle Scholar
  26. [26]
    Thomas B, Mohanakumar KP. Melatonin protects against oxidative stress caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the mouse nigros-tiratum. J Pineal Res 2004, 36: 25–32.PubMedCrossRefGoogle Scholar
  27. [27]
    Thomas B, Saravanan KS, Mohanakumar KP. In vitro and in vivo evidences that antioxidant action contributes to the neuroprotective effects of the neuronal nitric oxide synthase and monoamine oxidase-B inhibitor, 7-nitroindazole. Neurochem Int 2008, 52: 990–1001.PubMedCrossRefGoogle Scholar
  28. [28]
    Sengupta T, Mohanakumar KP. 2-Phenylethylamine, a constituent of chocolate and wine, causes mitochondrial complex-I inhibition, generation of hydroxyl radicals and depletion of striatal biogenic amines leading to psycho-motor dysfunctions in Balb/c mice. Neurochem Int 2010, 57: 637–646.PubMedCrossRefGoogle Scholar
  29. [29]
    Gluck MR, Zeevalk GD. Inhibition of brain mitochondrial respiration by dopamine and its metabolites: implications for Parkinson’s disease and catecholamine-associated diseases. J Neurochem 2004, 91: 788–795.PubMedCrossRefGoogle Scholar
  30. [30]
    Kawano T, Pinontoan R, Uozumi N, Morimitsu Y, Miyake C, Asada K, et al. Phenylethylamine-induced generation of reactive oxygen species and ascorbate free radicals in tobacco suspension culture: mechanism for oxidative burst mediating Ca2+ influx. Plant Cell Physiol 2000, 41: 1259–1266.PubMedCrossRefGoogle Scholar
  31. [31]
    Ortmann R, Schaub M, Felner A, Lauber J, Christen P, Waldmeier PC. Phenylethylamine-induced stereotypes in the rat: a behavioral test system for assessment of MAO-B inhibitors. Psychopharmacology (Berl) 1984, 84: 22–27.CrossRefGoogle Scholar
  32. [32]
    Lapin IP. Antagonism by CPP (+/−)-3-(2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid, of beta-phenylethylamine (PEA)-induced hypermotility in mice of different strains. Pharmacol Biochem Behav 1996, 55: 175–178.PubMedCrossRefGoogle Scholar
  33. [33]
    Barroso N, Rodriguez M. Beta-Phenylethylamine regulation of dopaminergic nigrostriatal cell activity. Brain Res 1995, 12: 201–204.Google Scholar
  34. [34]
    Barroso N, Rodriguez M. Action of β-phenylethylamine and related amines on nigrostriatal dopamine neurotransmission. Eur J Pharmacol 1996, 297: 195–203.PubMedCrossRefGoogle Scholar
  35. [35]
    Sato S, Tamura A, Kitagawa S, Koshiro A. A kinetic analysis of the effects of beta-phenylethylamine on the concentrations of dopamine and its metabolites in the rat striatum. J Pharm Sci 1997, 86: 487–496.PubMedCrossRefGoogle Scholar
  36. [36]
    Sindhu KM, Banerjee R, Senthilkumar KS, Saravanan KS, Raju BC, Rao JM, et al. Rats with unilateral median forebrain bundle, but not striatal or nigral, lesions by the neurotoxins MPP+ or rotenone display differential sensitivity to amphetamine and apomorphine. Pharmacol Biochem Behav 2006, 84: 321–329.PubMedCrossRefGoogle Scholar
  37. [37]
    Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nat Neurosci 2000, 3: 1301–1306.PubMedCrossRefGoogle Scholar
  38. [38]
    Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006, 443: 787–795.PubMedCrossRefGoogle Scholar
  39. [39]
    Hauser DN, Hastings TG. Mitochondrial dysfunction and oxidative stress in Parkinson’s disease and monogenic parkinsonism. Neurobiol Dis 2013, 51: 35–42.PubMedCrossRefGoogle Scholar
  40. [40]
    Hashimoto M, Hsu LJ, Xia Y, Takeda A, Sisk A, Sundsmo M, et al. Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro. Neuroreport 1999, 10: 717–721.PubMedCrossRefGoogle Scholar
  41. [41]
    Souza JM, Giasson BI, Chen Q, Lee VM, Ischiropoulos H. Dityrosine cross-linking promotes formation of stable alpha-synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. J Biol Chem 2000, 275: 18344–18349.PubMedCrossRefGoogle Scholar
  42. [42]
    Giasson BI, Ischiropoulos H, Lee VM, Trojanowski JQ. The relationship between oxidative/nitrative stress and pathological inclusions in Alzheimer’s and Parkinson’s diseases. Free Radic Biol Med 2002, 32: 1264–1275.PubMedCrossRefGoogle Scholar
  43. [43]
    Dawson TM, Dawson VL. Molecular pathways of neurodegeneration in Parkinson’s disease. Science 2003, 302: 819–822.PubMedCrossRefGoogle Scholar
  44. [44]
    Ghee M, Fournier A, Mallet J. Rat alpha-synuclein interacts with Tat binding protein 1, a component of the 26S proteasomal complex. J Neurochem 2000, 75: 2221–2224.PubMedCrossRefGoogle Scholar
  45. [45]
    Snyder H, Mensah K, Theisler C, Lee J, Matouschek A, Wolozin B. Aggregated and monomeric α-synuclein bind to the S6 proteasomal protein and inhibit proteasomal function. J Biol Chem 2003, 278: 11753–11759.PubMedCrossRefGoogle Scholar
  46. [46]
    Sherman MY, Goldberg AL. Cellular defences against unfolded proteins: a cell biologist thinks about neurodegenerative diseases. Neuron 2001, 19: 15–32.CrossRefGoogle Scholar
  47. [47]
    Lee HJ, Shin SY, Choi C, Lee YH, Lee SJ. Formation and removal of alpha-synuclein aggregates in cells exposed to mitochondrial inhibitors. J Biol Chem 2002, 277: 5411–5417.PubMedCrossRefGoogle Scholar
  48. [48]
    Sherer TB, Betarbet R, Testa CM, Seo BB, Richardson JR, Kim JH, et al. Mechanism of toxicity in rotenone models of Parkinson’s disease. J Neurosci 2003, 23: 10756–10764.PubMedGoogle Scholar
  49. [49]
    Betarbet R, Canet-Aviles RM, Sherer TB, Mastroberardino PG, McLendon C, Kim JH, et al. Intersecting pathways to neurodegeneration in Parkinson’s disease: effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system. Neurobiol Dis 2006, 22: 404–420.PubMedCrossRefGoogle Scholar
  50. [50]
    Chou AP, Li S, Fitzmaurice AG, Bronstei JM. Mechanisms of rotenone-induced proteasome inhibition. Neurotoxicology 2010, 4: 367–372.CrossRefGoogle Scholar
  51. [51]
    Manning-Bog AB, McCormack AL, Li J, Uversky VN, Fink AL, Di Monte DA. The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha synuclein. J Biol Chem 2002, 277: 1641–1644.PubMedCrossRefGoogle Scholar
  52. [52]
    Vila M, Vukosavic S, Jackson-Lewis V, Neystat M, Jakowec M, Przedborski S. Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the Parkinsonian toxin MPTP. J Neurochem 2000, 74: 721–729.PubMedCrossRefGoogle Scholar
  53. [53]
    McNaught KS, Perl DP, Brownell AL, Olanow CW. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson’s disease. Ann Neurol 2004, 56: 149–162.PubMedCrossRefGoogle Scholar
  54. [54]
    Olanow CW, McNaught KS. Ubiquitin-proteasome system and Parkinson’s disease. Mov Disord 2006, 21: 1806–1823.PubMedCrossRefGoogle Scholar
  55. [55]
    Sullivan PG, Dragicevic NB, Deng JH, Bai Y, Dimayuga E, Ding Q, et al. Proteasome inhibition alters neural mitochondrial homeostasis and mitochondria turnover. J Biol Chem 2004, 279: 20699–20707.PubMedCrossRefGoogle Scholar
  56. [56]
    Petrucelli L, O’Farrell C, Lockhart PJ, Baptista M, Kehoe K, Vink L, et al. Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron 2002, 36: 1007–1019.PubMedCrossRefGoogle Scholar
  57. [57]
    Tatton NA. Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson’s disease. Exp Neurol 2000, 166: 29–43.PubMedCrossRefGoogle Scholar
  58. [58]
    Hetherington MM, MacDiarmid JI. “Chocolate addiction”: a preliminary study of its description and its relationship to problem eating. Appetite 1993, 21: 233–246.PubMedCrossRefGoogle Scholar
  59. [59]
    Lee KW, Kim YJ, Lee HJ, Lee CY. Cocoa has more phenolic phytochemicals and a higher antioxidant capacity than teas and red wine. J Agric Food Chem 2003, 51: 7292–7295.PubMedCrossRefGoogle Scholar
  60. [60]
    Ruan H, Yang Y, Zhu X, Wang X, Chen R. Neuroprotective effects of (+/−)-catechin against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine(MPTP)-induced dopaminergic neurotoxicity in mice. Neurosci Lett 2009, 450: 152–157.PubMedCrossRefGoogle Scholar
  61. [61]
    Kim JS, Kim JM, O JJ, Jeon BS. Inhibition of inducible nitric oxide synthase expression and cell death by (−)-epigallocatechin-3-gallate, a green tea catechin, in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease. J Clin Neurosci 2010, 17: 1165–1168.PubMedCrossRefGoogle Scholar
  62. [62]
    Mennen LI, Walker R, Bennetau-Pelissero C, Scalbert A. Risks and safety of polyphenol consumption. Am J Clin Nutr 2005, 81: 326S–329S.PubMedGoogle Scholar
  63. [63]
    Arts IC, Hollman PC. Polyphenols and disease risk in epidemiologic studies. Am J Clin Nutr 2005, 81: 317S–325S.PubMedGoogle Scholar

Copyright information

© Shanghai Institutes for Biological Sciences, CAS and Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Anupom Borah
    • 1
    Email author
  • Rajib Paul
    • 1
  • Muhammed Khairujjaman Mazumder
    • 1
  • Nivedita Bhattacharjee
    • 1
  1. 1.Department of Life Science and BioinformaticsAssam UniversitySilcharIndia

Personalised recommendations